Table 2.
Rates of spontaneous reporting of Guillain Barré syndrome between countries
| All mRNA-based COVID-19 vaccines | Tozinameran | Elosameran | All adenovirus-based COVID-19 vaccines | ChAdOx1 nCoV-19 | Ad26.CoV2.S | |
|---|---|---|---|---|---|---|
| All countriesa | ||||||
| No. cases | 1232 | 952 | 280 | 610 | 349 | 261 |
| No. doses | 770,856,446 | 573,575,606 | 197,280,840 | 95,246,095 | 68,721,497 | 26,524,598 |
| Reporting rate [95% CI] per million dose administered | 1.60 [1.51–1.69] | 1.66 [1.56–1.77] | 1.42 [1.26–1.60] | 6.40 [5.91–6.93] | 5.08 [4.56–5.64] | 9.84 [8.68–11.11] |
| All EU countries | ||||||
| No. cases | 337 | 293 | 44 | 434 | 345 | 89 |
| No. doses | 406,708,824 | 358,078,048 | 48,630,776 | 79,304,511 | 66,730,990 | 12,573,521 |
| Reporting rate [95% CI] per million dose administered | 0.83 [0.74–0.92] | 0.82 [0.74–0.92] | 0.90 [0.66–1.21] | 5.47 [4.97–6.01] | 5.17 [4.64–5.75] | 7.08 [5.69–8.71] |
| Selected EU countriesb | ||||||
| Austria | 0.61 [0.20–1.43] | 0.70 [0.23–1.63] | 8.37 [4.69–13.81] | 8.31 [4.42–14.21] | 8.81 [1.07–31.84] | |
| Belgium | 0.76 [0.35–1.44] | 0.66 [0.27–1.37] | 1.56 [0.19–5.62] | 3.48 [1.74–6.23] | 3.90 [1.95–6.98] | –c |
| France | 1.17 [0.94–1.45] | 1.21 [0.96–1.51] | 0.87 [0.35–1.80] | 6.52 [4.94–8.45] | 6.44 [4.78–8.49] | 7.21 [2.90–14.85] |
| Germany | 1.28 [1.05–1.55] | 1.26 [1.02–1.54] | 1.44 [0.77–2.46] | 8.27 [6.89–9.84] | 7.37 [5.95–9.03] | 12.56 [8.65–17.64] |
| Italy | 0.53 [0.36–0.75] | 0.52 [0.34–0.75] | 0.61 [0.20–1.42] | 4.85 [3.74–6.18] | 4.33 [3.24–5.68] | 9.23 [4.92–15.79] |
| Netherlands | 1.05 [0.63–1.64] | 0.93 [0.52–1.53] | 2.09 [0.57–5.34] | 5.58 [3.41–8.62] | 4.64 [2.47–7.94] | 8.96 [3.60–18.45] |
| Portugal | 0.67 [0.27–1.39] | 0.56 [0.18–1.31] | 1.33 [0.16–4.81] | 6.70 [4.15–10.24] | 5.94 [3.17–10.17] | 8.45 [3.65–16.64] |
| Spain | 0.49 [0.31–0.73] | 0.48 [0.29–0.74] | 0.58 [0.16–1.48] | 5.25 [4.01–6.74] | 5.15 [3.82–6.79] | 5.75 [2.87–10.29] |
| Sweden | 0.98 [0.47–1.81] | 0.90 [0.39–1.77] | 1.54 [0.19–5.55] | 9.01 [4.66–15.75] | 9.01 [4.66–15.75] | –d |
| USA | ||||||
| No. cases | 869 | 640 | 229 | 170 | 170 | |
| No. doses | 342,208,275 | 200,551,649 | 141,656,626 | 13,892,386 | –e | 13,892,386 |
| Reporting rate [95% CI] per million dose administered | 2.54 [2.37–2.7] | 3.19 [2.95–3.45] | 1.62 [1.41–1.84] | 12.24 [10.47–14.22] | 12.24 [10.47–14.22] | |
CI confidence interval, EU European Union
aData include regions or countries with available cumulative data on the number of doses of each vaccine administered as of 15 August 2021 [11] and that contributed to reporting in VigiBase (at least one case, regardless of the vaccine). Besides the European Union and the US, five other countries contributed to the data (Ecuador, Iceland, Norway, Switzerland, and Uruguay)
bFor EU countries, reporting rates per million doses administered were given only for those that contributed to at least 20 cases of Guillain Barré syndrome associated with COVID-19 vaccines
cNo report in VigiBase
dNot used in Sweden
eNot used in the US